Aoyi Tech Secures Nearly RMB 100 Million in Series B++ Financing to Accelerate Brain-Computer Interface and Robotics Development

VCBeat learned第一时间 that recently, OYMotion Technology Co., Ltd. (hereinafter referred to as "OYMotion"), which focuses on brain-computer interface and robotics, announced the completion of nearly 100 million yuan in B++ round financing. This round of financing was led byInfinity Capital, Assets Management Co., Ltd., Zhejiang Province Development under Zhejiang Provincial State-owned Capital Operation Co., Ltd., and Vantage CapitalCo-investment,Krypton Agent CapitalAppointed as a long-term financial advisor. This is a new round of financing that has been quickly closed within three months after OYMotion completed its Series B+ funding at the end of 2024, fully demonstrating OYMotion's strong development momentum and high market recognition.

In 2015, OYMotion was officially established in Shanghai's Zhangjiang High-Tech Park. As one of the few innovative companies in China that simultaneously masters two core underlying technologies—brain-computer interface and robotics—OYMotion has consistently focused on the cross-integration of brain science and robotics technology. In the field of brain science, OYMotion has built a medical-grade neuro-interaction software and hardware integrated infrastructure platform based on its self-developed brain/muscle-computer interface technology, with over 80 patents currently granted. Its product portfolio includes the OB series of brain-computer interfaces, the OHand™ series of intelligent bionic hands, and the ORF series of neuro-rehabilitation exoskeletons.

Since its launch in 2020, the OHand™ intelligent bionic hand has quickly captured market share from imported products due to its cutting-edge technology and exceptional cost performance. In 2023, the OHand™ bionic hand successively obtained FDA/CE certifications and received the U.S. PDAC commercial insurance reimbursement code last year. It has taken the lead in overseas commercialization across multiple countries and regions worldwide, including the United States, the Middle East, Russia, Ukraine, and India. OYMotion's bionic hand has become a hallmark of "Made in China."

The ORF series of neurorehabilitation exoskeleton products by OYMotion has now entered the registration process. This product is mainly aimed at patients with motor dysfunction caused by stroke and peripheral nerve damage. Through the innovative product form of "neural interface + exoskeleton robot," it provides a complete solution that can achieve both rehabilitation and assistance for this patient population.

OYMotion Finger Exoskeleton Product ORF-7000

OYMotion Intelligent EEG Machine OB3000

OYMotion Intelligent Bionic Hand OHand™

OYMotion is the earliest team in China that has focused on the research of robotic hands. Since 2017, it has completed dozens of iterations and successfully promoted the implementation of robotic hands in various scenarios, such as intelligent bionic hands integrated with neural interfaces (EMG) for amputees, multiple dexterous hand products for embodied intelligence customers, and finger joint exoskeleton robot products for people with hand dysfunction. As one of the few manufacturers with mass production experience and batch delivery capabilities in the current market, OYMotion has achieved a balance among "cost-system parameters-stability" by building multi-scenario SKUs, becoming an important player in the first tier of dexterous hand technology. Currently, OYMotion is continuously striving for product innovation. The new generation of dexterous hand, ROH-AP001, will have sensing capabilities such as touch and pressure, and is expected to be officially launched in the market soon.

OYMotion's Dexterous Hand Application in the Embodied Robotics Field

This round of financing will inject strong momentum into OYMotion, helping the company achieve leapfrog development in multiple key areas. The funds will be mainly used to accelerate the market launch of the finger joint rehabilitation exoskeleton robot, while also further optimizing the continuous improvement of the intelligent bionic hand and dexterous hand products. After this round of financing, the company will further establish a world-leading standardized production system, optimize production processes, and achieve a 100% increase in annual production capacity. In addition, OYMotion will further advance its global market layout, providing higher quality and more efficient solutions for customers worldwide.

OYMotion Participates in the 137th Canton Fair On-site

OYMotion's Booth at the Canton Fair CCTV Live Broadcast

OYMotion Founder Hua Liang Ni expressed: Thanks to the trust and continuous support of both new and existing shareholders, completing two rounds of financing in a short span of a few months is not only an endorsement from the shareholders but also a reflection of the company's robust growth potential. After the completion of this round of financing, the OYMotion team will adopt a more open attitude to deepen cooperation with industry partners, jointly promoting the industrialization process of the brain science and robotics industries, and striving forward towards becoming a leading global technology enterprise.

Infinity CapitalInfinity (Zhuhai) Venture Capital Management Co., Ltd. has long been highly attentive to emerging industries that integrate medical care, robotics, and AI, represented by brain-computer interfaces and embodied intelligence. OYMotion, as a leading enterprise in this field, has taken the lead in exploring practical application scenarios such as intelligent bionic hands, thanks to its profound strategic insight and engineering capabilities. This not only brings good news to a wide range of disadvantaged groups but also provides an important carrier and underlying technology for the development of new productive forces. We are very pleased to be fellow travelers with OYMotion and look forward to helping it reach new heights through this investment.

Assets Management Co., Ltd., Zhejiang Province DevelopmentIndicates:OYMotion Focuses on the Cross-Innovation of Brain Science and Robotics, Leading the First Tier of Dexterous Hand Industry in China. This investment is a significant move by Assets Management Co., Ltd., Zhejiang Province Development to promote the integration and innovation of cutting-edge technologies like brain-inspired intelligence with robotics, and to upgrade China's embodied intelligence industry chain collaboratively. Going forward, under the guidance of the Yangtze River Delta Integration Strategy, Assets Management Co., Ltd., Zhejiang Province Development will leverage the synergies between Shanghai and Zhejiang, utilize complementary functions, and continuously provide diversified post-investment empowerment support to enterprises. The company will focus on strategic investments and capital operations, propelling OYMotion to become a leading enterprise in core components of embodied intelligence.

VMD CapitalOYMotion: Driven by the global wave of intelligent transformation in manufacturing and breakthroughs in artificial intelligence technology, the intelligent manufacturing and robotics industries are embracing explosive growth opportunities. Building on its technical expertise in electromyography signal processing and bionic hand development, OYMotion has expanded deeply into vertical scenarios within rehabilitation medicine, establishing a robust business foundation. At the same time, the company has further leveraged its excellent capabilities in supply chain integration and commercial execution to unlock a strategic entry point in the embodied intelligent robotics field, forming a multi-driven business structure. As a long-term value investor, VCBeat looks forward to utilizing its industrial advantages to move forward alongside OYMotion, continuously injecting momentum into the industry’s innovative development.

Infinity Capital Management Co., Ltd. ("Infinity Capital" for short) is an equity investment platform under Huafa Group, a leading state-owned enterprise in Zhuhai and a member of the top 500 enterprises in China. It also serves as the core business entity of Infinity Group, a well-known overseas investment management institution. The company primarily operates domestic RMB fund businesses and cross-border investment activities, with operations spanning more than 10 cities both domestically and internationally. It has established five major business segments: Greater Healthcare, East China, South China, Southwest China, and Hong Kong & Overseas Regions. Infinity Capital has made key investments in sectors such as new energy, integrated circuits, artificial intelligence, quantum technology, healthcare and life sciences, advanced manufacturing, and new materials. In recent years, the company has maintained steady growth in its investment performance. Notable projects that have successfully gone public include Ever Victory Medical (01612.HK), Asymchem Laboratories (002821.SZ), Huati Technology (603679.SH), L&C Precision (002921.SZ), Lihu Lake Co., Ltd. (300694.SZ), Lanjian Intelligence (688557.SH), New Glory (688663.SH), HaiChuang Pharma (688302.SH), Transwarp Technology (688259.SH), Silinjie (688115.SH), Laikang Medicine (2105.HK), and Zhirui Co., Ltd. (301587.SZ). Additionally, Hongtu Separator and IOPtima were acquired by listed companies King Crown Co., Ltd. (300510.SZ) and Kanghong Pharmaceuticals (002773.SZ), respectively.

Assets Management Co., Ltd., Zhejiang Province Development adheres to the mission of "serving major strategies, serving the real economy, and serving state-owned enterprises," and is committed to "participating in all types of capital market businesses and providing comprehensive services for capital operation projects of high-quality listed companies within the province." Its main focus areas include private placements, strategic placements, mergers and acquisitions, restructuring, private securities, and other primary-and-a-half and secondary market businesses, as well as mature equity investments in niche markets. The company continuously optimizes its investment layout and improves quality and efficiency. By the end of 2024, the company's total assets reached 2.66 billion yuan, with over 130 investment projects and an investment amount exceeding 6.3 billion yuan. Among these, it has supported more than 50 listed enterprises in their transformation and development and nurtured nearly 80 start-up companies, helping them go public on domestic and overseas capital markets.

VMD Capital is a newly established industrial capital focusing on healthcare, hard technology, and consumer-related fields, covering all stages of a company's entire lifecycle. The company has a deep understanding of the development and operation patterns of local enterprises and possesses profound industry knowledge, having successfully invested in several outstanding companies.